N/A
N=31
A Multi-Center Trial of Botox for Severe Urge Urinary Incontinence
Urinary Incontinence
Bottom Line
View on ClinicalTrials.gov: NCT00345332 ↗Enrolled (actual)
31
Serious AEs
0.0%
Results posted
Jul 2017
Primary outcome: Primary: Incontinent Episodes Per Day — 7.34; 3.90 incontinence episodes per day — p=<0.01
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Botox (Drug); Placebo (Drug)
- Age
- Adult, Older Adult · 21+ yrs
- Sex
- Female
- Sponsor
- University of Rochester
- Primary completion
- May 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Incontinent Episodes Per Day |
7.34; 3.90 | <0.01 sig |
| SECONDARY Number of Incontinence Pads Used Per Day |
5.18; 3.13 | <0.01 sig |
Summary
The purpose of the study is to determine how effective Botox is in reducing the amount of urine leaked and which dose of Botox is more effective and safe in those who have urinary urge incontinence.
Eligibility Criteria
Inclusion Criteria
- Female subjects 21-90 years of age
- subjects has urinary incontinence on 3 day bladder diary
- subject has severe incontinence
- urine dipstick or urine culture negative for urinary tract infection
- cystometrogram without stress urinary leakage
- must have failed at least one anti-cholinergic medication
- negative urine pregnancy test on day of administration of study medication
Exclusion Criteria
- history of carcinoma of the bladder
- presence of foreign body in the bladder, cystitis or other correctable etiology for Urge Urinary Incontinance
- gross fecal incontinence
- known allergy to sulfa or ciprofloxacin or to lidocaine
- any medical condition that may put the subject at increased risk with exposure to Botox
- females who are pregnant, breast-feeding, or planning a pregnancy during the study or who are of child-bearing potential
- known allergy to any of the components in the study medication
- prior documented resistance to Botox
- evidence of recent alcohol or drug abuse
- concurrent participation in another investigational drug or device study within 30 days
Data sourced from ClinicalTrials.gov (NCT00345332). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.